ArticleNature cancer2025

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

Wen Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.